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Abstract: Industrial lead toxicity is more common among miners. This type of toxicity occurs in two forms: acute and
chronic. Chronic toxicity is associated with different levels of brain dysfunction, motor impairment, cognitive
dysfunction, and neuropsychiatric problems, including depression, anxiety, irritability, and emotional disorders.
However, quadriplegia induced by chronic toxicity is very rare. Here we report a 37-year-old male patient with
a history of desert hunting, where he used to roll lead bullets in his mouth, who was admitted with sensory
impairment, muscle weakness, and quadriplegia and final diagnosis of lead toxicity.
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1. Introduction
Industrial lead poisoning is one of the oldest types of occupa-
tional poisoning, which dates back to at least 5000 years ago.
Nonorganic lead can be found in workers of ceramic glaze,
food canning, color, and cosmetic companies. There is also
nonorganic lead in drinking water, industrial dust, and motor
vehicle exhaust. Lead levels are higher among adult workers
who are in contact with industrial lead. This type of lead is
mainly absorbed through the lungs and gastrointestinal tract
(1, 2).
Neurotoxicity occurs due to physiological and neurological
changes, which are caused by exposure to toxic agents. It may
cause changes in cognition, memory, and mood or result in
the development of psychiatric disorders (3). Neurotoxicity
induced by heavy metals, including lead, mercury, and ar-
senic, has been explored more. This type of toxicity has two
common forms: acute and chronic. Symptoms of acute poi-
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soning include nausea, headache, cognitive problems, and
emotional disorders.
Chronic exposure often occurs in industrial workplaces. In
chronic exposure, symptoms are mostly neurological and
psychiatric, including depression, anxiety, and irritability.
Chronic exposure to lead may cause symptoms, such as fa-
tigue, brain dysfunction, motor impairment, and cognitive
dysfunction in general (4). Studies show that reduction of
sensory responses and cognitive impairment occur in male
workers with blood lead levels ≥ 40 µg/100ml (5). Peripheral
motor neuropathy and reduced velocity of peripheral nerve
conduction have been also reported in some cases of chronic
lead toxicity (6, 7).
At high doses, lead toxicity causes irritability, headache, men-
tal fatigue, reduced concentration, memory loss, tremor, and
hallucinations. It may even result in quadriplegia, seizure,
delirium, coma, or death. In the event of lead toxicity, early
diagnosis, careful evaluation, and immediate treatment are
very important (8). Therefore, it is necessary to be familiar
with the rare symptoms of chronic lead toxicity.
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2. Case Presentation
The patient was a 37-year-old married man, who was a
hunter of wild desert animals and used to roll lead bullets
in his mouth. In the spring of 2015, he was referred to the
hospital with abdominal pain and tenderness which had ini-
tiated almost 30 days before his admission. The patient was
admitted to the surgical gastroenterology department due
to abdominal pain and tenderness, weight loss, loss of ap-
petite, and diffuse itching. On the tenth day of hospitaliza-
tion, the patient suddenly developed sensory impairment,
muscle weakness, and quadriplegia. With suspicion to su-
per acute toxicity, he was transferred to the poisoning depart-
ment.
The results of abdominal and pelvic computed tomography
(CT) scans were normal, just like the results of endoscopy
and colonoscopy. Moreover, the results of Doppler ultra-
sound and brain magnetic resonance imaging (MRI) were
normal. Electromyography (EMG) and nerve conduction ve-
locity (NCV) suggested axonal neuropathy in all the limbs.
The patient’s neurological symptoms, such as motor neu-
ropathy, quadriplegia, walking disability, and paresthesia,
were exacerbated since the time of admission. Cognitive
disorders, including thought disorders, accompanied by dis-
tress, anxiety, and delirium, were evident in the patient.
Laboratory findings showed increased levels of liver en-
zymes (AST: 220 unit/L, ALT;120 unit/L), bilirubin(Total: 3
mg/dl with Direct: 1/2 mg/dl), lactate dehydrogenase (LDH:
750 unit/L), amylases (220 unit/L), leukocytosis (22000/m3),
and anemia (Mean Hemoglobin: 8.5 g/dl, MCV: 75). No
basophilic stippling was observed in the peripheral blood
smear during hospitalization.
The patient’s medical history indicated chronic abdominal
pain about four years before his referral for which he was
hospitalized for several days and was discharged with a good
general condition. With suspicion of lead toxicity the serum
lead level was measured, which indicated a lead level of
150 µcg/dL. Considering the likelihood of acute lead poi-
soning with repeated attacks, chelation therapy was applied
according to the standard protocols of the medical toxicol-
ogy book. Therapeutic instructions included Livergol tablets,
adenosine monophosphate (AMP), bronchoalveolar lavage
(BAL), ethylenediaminetetraacetic acid (EDTA), calcium, and
sodium. During treatment with BAL, the patient experienced
stress disorders, exacerbated delirium, and tachycardia.
Methadone was initiated to overcome the suspected drug
withdrawal syndrome. However, the symptoms did not re-
solve, and sedative medications such as midazolam were
used to manage them. After two days of treatment with
BAL, which led to restlessness, distress, and tachycardia, BAL
treatment was temporarily terminated. After stabilization,
BAL was continued in the intensive care unit (ICU).
BAL was continued with the same dosage as the patient
was hospitalized in the ICU. His general condition gradu-
ally improved, and BAL-induced complications (tachycar-
dia, hypertension, and distress), which persisted for three to
five days, were resolved. Once the lead level reached 120
µcg/dL, treatment was continued with ETDA+BAL with the
same dosage. After three days of treatment, the lead level
reached 85 µcg/dL. Therefore, BAL was terminated and sub-
stituted with oral succimer.
After three days of treatment with succimer, the lead level
reached 65 µcg/dL. At this lead level, BAL and EDTA admin-
istration was terminated, and succimer was continued with
the same dosage. During treatment, the ferritin level became
normal. After 15 days of treatment, the patient’s anemia was
improved and the level of liver enzymes gradually decreased
and eventually reached the normal level after three weeks of
treatment. After four months of treatment with succimer, the
lead level reached 60 µcg/dL; treatment continued with suc-
cimer (divided doses every 12 hours). However, neurological
symptoms, specifically muscle weakness and neuropathy, re-
mained unchanged. With proper physiotherapy, most disor-
ders, including muscle weakness of the upper and lower ex-
tremities, improved. After one year of follow-up, he was com-
pletely alert, without any neurological deficits; his cognition
and perception also improved.
3. Discussion
Several studies have shown that industrial lead exposure can
cause memory impairment and reduce the processing speed,
reading comprehension, motor skills, and executive func-
tions. Moreover, anxiety, depression, and phobia are prob-
able in these patients. In our study, the patient suffered from
tremor, paresthesia, peripheral neuropathy, quadriplegia,
and walking disability. In a case report by Beig Mohammadi
et al., entitled “Quadriplegia induced by lead-contaminated
opium”, a patient was examined with quadriplegia. Despite
the resolution of all symptoms and reduction of blood lead
level, the patient was discharged with quadriplegia (9). In the
present report, which is only different from the mentioned
study in terms of the contamination source, the patient was
completely recovered after the treatment period and one-
year follow-up.
A study by D. A. Gidlow showed that in industrial workers
with lead levels above 40 µg/100ml, neurotoxicity was char-
acterized by motor deficiency and cognitive problems and
even in some cases by peripheral neuropathy. Memory and
concentration problems, besides visual impairment, occur at
lead levels higher than 50 µg/100ml (1). A study by Sansar
W, which was conducted on mice, found that lead levels of
100 µg/100ml can cause changes in the glial and neuronal
systems and result in functional and behavioral impairments
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(10).
In a study of 2930 cases, Robert A. Goyer concluded that in-
fants, whose umbilical cord blood lead levels were higher
than 10 µg/100ml, had sensory, motor, and visual impair-
ments, as well as cognitive problems during development
(11). Moreover, in a review study, Lisa H. Mason concluded
that high levels of lead toxicity in workers cause seizure,
lethargy, and coma. In acute cases of lead toxicity, reversible
neuropathy occurs (8).
In another study, Wilhelm M found that cognitive and be-
havioral changes occur at a lead level of 100 µg/100ml; these
disorders were more serious in younger patients (12). In our
study, long-term lead exposure and high lead level resulted
in neuropathy, numbness, and quadriplegia, which gradually
resolved with proper chelation therapy. Moreover, in a study
on industrial workers Baker EL found that workers with lead
levels above 40 µg/100ml experienced problems, such as
mood and emotional disorders, exacerbated depression,
confusion, anger, and increased tension and fatigue. In the
long run, these workers experienced complications, such as
memory, cognitive, visual, and verbal impairments (13). In
this study, motor problems were not reported. Slight motor
problems have been reported in several studies, although
quadriplegia and walking disability were not found in the
literature; quadriplegia was only reported in some cases.
In this study, we reported a patient with a lead level of
150 µg/100ml, associated with quadriplegia and walking
disability.
4. Conclusion:
Workers who are in contact with industrial lead are exposed
to chronic lead toxicity. Delayed detection of serious symp-
toms, such as cognitive, sensory, and functional disorders,
can be life-threatening for these workers. Therefore, workers
exposed to industrial lead are recommended to undergo
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